Depresyon Nörobiyolojisi ve Psikofarmakolojik Tedavinin Temel İlkeleri
Özet
Depresyon, zihinsel ve fiziksel alanlarda işlevselliği olumsuz etkileyen, yaygın bir halk sağlığı sorunudur. Patofizyolojisinde monoamin (serotonin, noradrenalin, dopamin) nörotransmitterlerindeki değişimler, HPA ekseni anormallikleri, azalmış nöroplastisite, BDNF seviyelerindeki düşüş, glutamat ve GABA sistemindeki farklılıklar ile proinflamatuar sitokin artışları gibi multifaktöryel mekanizmalar rol oynamaktadır. Yapısal ve işlevsel beyin görüntülemeleri, lateral ventriküllerde genişleme ve anterior singulat korteks ile amigdala gibi bölgeleri içeren devrelerde anormal etkileşimler göstermektedir. Tedavide temel öncelik hastanın güvenliğinin sağlanması ve intihar riskinin değerlendirilmesidir. Akut ve kronik dönem yönetiminde farmakoterapi ve psikoterapi kombinasyonu tek başına ilaç tedavisine kıyasla daha üstün sonuçlar vermektedir. Akut tedavide plaseboya oranla daha etkili olan antidepresanlar arasında, düşük yan etki profilleri ve yüksek dozda güvenilirlikleri nedeniyle SSRI grubu ilaçlar ilk seçenek olarak tercih edilmektedir. Dirençli vakalarda tedaviye lityum veya atipik antipsikotikler eklenebileceği gibi EKT, TMS ve VNS gibi nörostimülasyon yöntemleri ile uyku yoksunluğu ve parlak ışık tedavilerinden yararlanılmaktadır. Destekleyici psikoterapi, BDT, davranışsal aktivasyon ve kişilerarası terapiler gibi yapılandırılmış yöntemler ise özellikle hafif ve orta şiddetteki depresyonda etkilidir. Sonuç olarak, kronik ve nüksedici seyir gösteren bu bozukluğun akut sağaltımı kadar nükslerin önlenmesi de kritik önem taşımaktadır.
Depression is a prevalent public health issue that negatively impacts mental and physical functioning. In its pathophysiology, multifactorial mechanisms play a role, including alterations in monoamine (serotonin, norepinephrine, dopamine) neurotransmitters, HPA axis abnormalities, decreased neuroplasticity, reductions in BDNF levels, variations in glutamate and GABA systems, and increased proinflammatory cytokines. Structural and functional brain imaging demonstrates enlargement in lateral ventricles and abnormal interactions within circuits involving areas such as the anterior cingulate cortex and amygdala. The primary priority in treatment is ensuring patient safety and assessing suicide risk. In acute and chronic management, the combination of pharmacotherapy and psychotherapy yields superior outcomes compared to drug treatment alone. Among antidepressants, which are more effective than placebo in acute treatment, SSRI group drugs are preferred as the first-line choice due to their low side effect profiles and safety in high doses. In resistant cases, lithium or atypical antipsychotics can be augmented, or neurostimulation methods like ECT, TMS, and VNS, alongside sleep deprivation and bright light therapies, can be utilized. Structured psychotherapies such as supportive, CBT, behavioral activation, and interpersonal therapies are effective, particularly in mild to moderate depression. Consequently, preventing relapses is as critical as acute treatment for this chronic and recurrent disorder.
Referanslar
Andreasen NC BD. Mood Disorders. Introductory Textbook of Psychiatry. Arlington: American Psychiatric Publishing; 2001. p. 269-314.
Dean J, Keshavan M. The neurobiology of depression: An integrated view. Asian journal of psychiatry. 2017;27:101-11.
Harrison P, Cowen P, Burns T, Fazel M. Depression. Shorter Oxford textbook of psychiatry. Seventh Edition ed: Oxford university press; 2017. p. 193-225.
Moberg T, Nordström P, Forslund K, Kristiansson M, Asberg M, Jokinen J. CSF 5-HIAA and exposure to and expression of interpersonal violence in suicide attempters. Journal of affective disorders. 2011;132(1-2):173-8.
Stockmeier CA. Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. Journal of psychiatric research. 2003;37(5):357-73.
Meyer JH. Neurochemical imaging and depressive behaviours. Current topics in behavioral neurosciences. 2013;14:101-34.
Kambeitz JP, Howes OD. The serotonin transporter in depression: Meta-analysis of in vivo and post mortem findings and implications for understanding and treating depression. Journal of affective disorders. 2015;186:358-66.
Cowen PJ. Neuroendocrine and Neurochemical Processes in Depression. Psychopathology Review. 2016;a3(1):3-15.
Ruhé HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Molecular psychiatry. 2007;12(4):331-59.
Thase ME. Mood Disorders: Neurobiology. In: B.J. Sadock VAS, P. Ruiz, editor. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. ABD: Wolters Klüver / Lippincott Williams & Wilkins; 2009. p. 1664-75.
Escribá PV, Ozaita A, García-Sevilla JA. Increased mRNA expression of alpha2A-adrenoceptors, serotonin receptors and mu-opioid receptors in the brains of suicide victims. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2004;29(8):1512-21.
Castrén E, Võikar V, Rantamäki T. Role of neurotrophic factors in depression. Current opinion in pharmacology. 2007;7(1):18-21.
Park H, Poo MM. Neurotrophin regulation of neural circuit development and function. Nature reviews Neuroscience. 2013;14(1):7-23.
Yu H, Chen ZY. The role of BDNF in depression on the basis of its location in the neural circuitry. Acta pharmacologica Sinica. 2011;32(1):3-11.
Arnone D, Mumuni AN, Jauhar S, Condon B, Cavanagh J. Indirect evidence of selective glial involvement in glutamate-based mechanisms of mood regulation in depression: meta-analysis of absolute prefrontal neuro-metabolic concentrations. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2015;25(8):1109-17.
McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychological medicine. 2015;45(4):693-704.
Sarkhel S. Kaplan and Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry, 10(th) edition: Indian J Psychiatry. 2009 Oct-Dec;51(4):331.
Daban C, Vieta E, Mackin P, Young AH. Hypothalamic-pituitary-adrenal axis and bipolar disorder. The Psychiatric clinics of North America. 2005;28(2):469-80.
Saveanu RV, Nemeroff CB. Etiology of depression: genetic and environmental factors. The Psychiatric clinics of North America. 2012;35(1):51-71.
Juruena MF, Werne Baes CV, Menezes IC, Graeff FG. Early life stress in depressive patients: role of glucocorticoid and mineralocorticoid receptors and of hypothalamic-pituitary-adrenal axis activity. Current pharmaceutical design. 2015;21(11):1369-78.
Gold PW. The organization of the stress system and its dysregulation in depressive illness. Molecular psychiatry. 2015;20(1):32-47.
Bunevicius R, Prange AJ, Jr. Thyroid disease and mental disorders: cause and effect or only comorbidity? Current opinion in psychiatry. 2010;23(4):363-8.
Nanni V, Uher R, Danese A. Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: a meta-analysis. The American journal of psychiatry. 2012;169(2):141-51.
Steiger A, Kimura M. Wake and sleep EEG provide biomarkers in depression. Journal of psychiatric research. 2010;44(4):242-52.
Arnone D, McIntosh AM, Ebmeier KP, Munafò MR, Anderson IM. Magnetic resonance imaging studies in unipolar depression: systematic review and meta-regression analyses. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2012;22(1):1-16.
RS D. Neurochemical Theories of Depression. New York: Oxford University Press; 2009.
Aizenstein HJ, Andreescu C, Edelman KL, Cochran JL, Price J, Butters MA, et al. fMRI correlates of white matter hyperintensities in late-life depression. The American journal of psychiatry. 2011;168(10):1075-82.
Price JL, Drevets WC. Neural circuits underlying the pathophysiology of mood disorders. Trends in cognitive sciences. 2012;16(1):61-71.
Kaiser RH, Andrews-Hanna JR, Wager TD, Pizzagalli DA. Large-Scale Network Dysfunction in Major Depressive Disorder: A Meta-analysis of Resting-State Functional Connectivity. JAMA psychiatry. 2015;72(6):603-11.
National Institute for Clinical Excellence. Depression in adults: treatment and management. NICE guideline [NG222]. 2022.
Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. Journal of psychopharmacology (Oxford, England). 2015;29(5):459-525.
Barbui C, Cipriani A, Patel V, Ayuso-Mateos JL, van Ommeren M. Efficacy of antidepressants and benzodiazepines in minor depression: systematic review and meta-analysis. The British journal of psychiatry : the journal of mental science. 2011;198(1):11-6, sup 1.
David M. Taylor TREB, Allan H. Young. The Maudsley Prescribing Guidelines İn Psychiatry. 14 Edition ed. UK: Wiley Blackwell; 2021.
Morris JB, Beck AT. The efficacy of antidepressant drugs. A review of research (1958-1972). Archives of general psychiatry. 1974;30(5):667-74.
Cowen PJ, Anderson IM. New approaches to treating resistant depression. BJPsych Advances. 2018;21(5):315-23.
Whiting D, Cowen PJ. Drug information update: agomelatine. The Psychiatrist. 2018;37(11):356-8.
Nelson JC, Baumann P, Delucchi K, Joffe R, Katona C. A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. Journal of affective disorders. 2014;168:269-75.
Barbee JG, Thompson TR, Jamhour NJ, Stewart JW, Conrad EJ, Reimherr FW, et al. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. The Journal of clinical psychiatry. 2011;72(10):1405-12.
Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS medicine. 2013;10(3):e1001403.
Berry SM, Broglio K, Bunker M, Jayewardene A, Olin B, Rush AJ. A patient-level meta-analysis of studies evaluating vagus nerve stimulation therapy for treatment-resistant depression. Medical devices (Auckland, NZ). 2013;6:17-35.
Berlim MT, Van den Eynde F, Daskalakis ZJ. Efficacy and acceptability of high frequency repetitive transcranial magnetic stimulation (rTMS) versus electroconvulsive therapy (ECT) for major depression: a systematic review and meta-analysis of randomized trials. Depression and anxiety. 2013;30(7):614-23.
Ekers D, Webster L, Van Straten A, Cuijpers P, Richards D, Gilbody S. Behavioural activation for depression; an update of meta-analysis of effectiveness and sub group analysis. PloS one. 2014;9(6):e100100.
Driessen E, Hegelmaier LM, Abbass AA, Barber JP, Dekker JJ, Van HL, et al. The efficacy of short-term psychodynamic psychotherapy for depression: A meta-analysis update. Clinical psychology review. 2015;42:1-15.
Hemmeter UM, Hemmeter-Spernal J, Krieg JC. Sleep deprivation in depression. Expert review of neurotherapeutics. 2010;10(7):1101-15.
Lieverse R, Van Someren EJ, Nielen MM, Uitdehaag BM, Smit JH, Hoogendijk WJ. Bright light treatment in elderly patients with nonseasonal major depressive disorder: a randomized placebo-controlled trial. Archives of general psychiatry. 2011;68(1):61-70.
